CMA
HALO icon

Cedar Mountain Advisors’s Halozyme HALO Stock Holding History

Cedar Mountain Advisors’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.51K Hold
96
– – ﹤0.01% 573
2026
Q1 		$6.2K Buy
+96
New +$6.77K ﹤0.01% 589

Other funds holding HALO

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
AT
Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
KWM
Koa Wealth Management Encinitas, California $147M AUM 18.41% 1-Year Est. Return
BCA
Bernzott Capital Advisors Camarillo, California $250M AUM 26.89% 1-Year Est. Return
AAM
Augustine Asset Management Jacksonville, Florida $494M AUM 76.22% 1-Year Est. Return

Cedar Mountain Advisors's HALO Position: Q2 2026 in Review

Cedar Mountain Advisors held its Halozyme (HALO) position steady in Q2 2026 at 96 shares worth $7.51K. The position accounts for ﹤0.01% of the portfolio, ranked #573.

Cedar Mountain Advisors first reported a position in HALO in Q1 2026 and has held it in 2 quarters since. 108 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Cedar Mountain Advisors held 96 shares of Halozyme worth $7.51K as of Q2 2026.
  • Cedar Mountain Advisors left its Halozyme share count unchanged in Q2 2026.
  • Halozyme made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #573 holding.
  • Cedar Mountain Advisors first reported a position in Halozyme in Q1 2026 and has held it in 2 quarters since.
  • 108 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.